sur INTRASENSE (EPA:ALINS)
Intrasense Expands AI Solutions in Oncological Imaging
On June 5th, 2025, Intrasense, an AI-enhanced medical imaging solutions provider, updated its activities since announcing its strategic roadmap. Based in Montpellier, France, Intrasense structures its products around three AI-supported ranges recognized for their high clinical value in the oncological imaging sector.
The Myrian® platform stands as the core product. Integrating AI, it offers a variety of applications across specialties, ensuring quick and efficient analysis of radiological exams. It is currently certified for use in nearly 40 countries.
DUOnco™, another key offering, automates lesion detection in CT scans. Recently certified for bone lesion detection, it assists radiologists in decision-making by minimizing overlooked lesions.
Lastly, Liflow® targets oncological monitoring with its AI-enhanced solution for CT-TAP scans, aiming to halve examination interpretation time.
Intrasense continues to strengthen its presence at major congresses, leveraging partnerships to enhance visibility and business opportunities.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INTRASENSE